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ABSTRACT 
A prospective, consecutive series of six patients with renal dysfunction as defined by 
abnormal serum creatinine underwent cemented primary THR for osteoarthritis and the 
elution characteristics of Simplex-Tobramycin bone cement were compared to a 
previously reported group of nine patients with normal renal function.  Blood, urine and 
drainage fluid specimens were collected for 72hours post-operatively.  Very high 
concentrations of tobramycin were seen in the drainage fluid, with no significant 
difference between the two groups (p<0.05).  Mean serum tobramycin levels peaked at 
3hours, and declined rapidly to reach negligible levels at 72hours in both groups with no 
significant difference (p<0.05).  Mean urinary tobramycin concentrations peaked at 
12hours, with rapid decline by 48hours in both groups.  Tobramycin was excreted 
significantly more slowly in the patients with renal dysfunction in the first 12hours 
(p=0.05), but not thereafter.  Although serum creatinine levels were higher in the renal 
group throughout the study, neither group had a significant change at 72hours compared 
to their preoperative level.  Excellent local delivery was achieved with minimal 
systemic concentrations in both groups and no change in preoperative renal function.  
Simplex-Tobramycin bone cement is an effective and safe means by which to deliver 
antibiotic following THR in patients with renal dysfunction. 
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INTRODUCTION 
Antibiotic-laden acrylic bone cement has become popular as a prophylactic measure 
against the devastating complication of deep infection following total hip replacement.  
Its use in combination with systemic antibiotics has proven most effective4,7.  
Commercially available gentamicin-impregnated cement and Simplex antibiotic cement 
with erythromycin (500mg) and colistin (240mg) (Howmedica, Limerick, Ireland) have 
been widely available, and their safety and pharmacokinetic profiles are well 
documented12,16.  Despite this, resistant strains of organism are providing renewed 
challenges in the management of infected total joint replacement13. 
 
Tobramycin may be a better antibiotic to admix with bone cement than currently 
available antibiotics.  At levels achievable at the operative site with tobramycin-
impregnated cement, all common gram negative and most gram positive organisms are 
susceptible, including organisms not susceptible with systemic administration13.  
Tobramycin is less ototoxic and nephrotoxic than gentamicin and has been proven to 
elute at higher concentrations than gentamicin from Palacos, Simplex and Zimmer 
cements8,11.   Tobramycin has already been successfully used in several studies where it 
was added to Simplex P in the operating room1,10,14.  Safe and effective bactericidal 
levels were swiftly established at the site of the implant, while serum concentrations 
were negligible after only 24 hours.   
 
Problems associated with the addition of tobramycin to bone cement include weakening 
of the cement, generation of antibiotic-resistant bacteria and systemic toxicity.  
Tobramycin has been proven not to effect the mechanical characteristics of Simplex 
bone cement2,6,9.    Clinically, the mixture of antibiotics to bone cement not only 
decreases infective loosening out to 14 years but also decreases the rate of aseptic 
loosening suggesting there are no clinical concerns with possible mechanical changes 
produced by the addition of antibiotics to cement3.  Rates of systemic toxicity, in 
particular renal impairment with the use of antibiotic cement are almost nonexistent.  In 
a prospective study, higher renal impairment rates were reported in patients treated with 
systemic dicloxicillin only (13%) as opposed to those treated with gentamycin 
impregnated cement only (0%) for prophylaxis during primary total hip replacement5.  
However, a recent case report documented acute renal failure after the use of a 
gentamycin impregnated spacer without any systemic antibiotics for a two stage 
revision total knee arthroplasty17.   
 
The pharmacokinetic profile of commercially prepared Simplex-Tobramycin bone 
cement has recently been published15.  However, the safety of routine use of tobramycin 
has not been documented with commercially prepared Simplex-Tobramycin bone 
cement (Howmedica, Limerick, Ireland; 1 gram tobramycin sulphate; 40g powder, 20ml 
liquid) in patients with renal dysfunction.  This study aims to compare the 
pharmacokinetic profile of tobramycin in blood, urine and at the operative site 
following the use of Simplex-Tobramycin bone cement in primary total hip replacement 
in patients with and without renal dysfunction. 
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MATERIALS AND METHODS 
Six consecutive patients who had evidence of pre-existing renal dysfunction, as defined 
by abnormal pre-operative serum creatinine (males>0.12;females>0.1mg/l) were 
included in this study.  This group of patients was compared to a previously reported 
group of nine patients with osteoarthritis with normal renal function who were selected 
prospectively for primary cemented total hip replacement.  All patients with active 
infection, malignancy at the operative site and known sensitivity to aminoglycosides or 
acrylic bone cement were excluded from the study group.  All patients received Keflin 
1g, 6 hourly for 4 doses.  Additional intravenous tobramycin was not used in these 
patients during the study period.   
 
One mix of Simplex-Tobramycin bone cement for the acetabular component and two 
mixes for the femoral component were used in all cases.  All drainage fluids and urine 
were collected for 48 hours after prosthesis implantation, divided into the time periods 
shown in Table 1.  Venous blood samples were collected in parallel and up to 72 hours.  
Tobramycin concentrations were assayed on a Dimension RxL clinical chemistry 
system using a PETINIA method (Particle enhanced turbinometric inhibition 
immunoassay).  The lower limit of detection for this assay is approximately 0.18 mg/l.  
Serum creatinine concentrations were also collected for each patient at the same time 
intervals and assays were also performed on the Dade Dimension RxL analyzer using a 
Jaffe reaction. 
 
Statistical analysis was performed using parametric and non-parametric testing as 
dictated by the type of data collated, using SPSS statistical package (SPSS Inc, Chicago, 
Illinois).  Where multiple testing was performed, Bonferroni’s correction for multiple 
testing was utilized and the p-value for significance adjusted accordingly. 
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RESULTS 
Patient demographics are presented for both groups in Table 2.  Serum creatinine levels 
were significantly higher (p = 0.001) in the patients with renal dysfunction, but all other 
variables were similar between the two groups. 
 
The data was tested for normality, which showed that other than the pre-operative 
variables, the data was non-parametric in nature.  Hence, these means were compared 
using the t-test, whereas for all other variables, the groups were compared using the 
Mann-Whitney U-test. 
 
Drainage fluid tobramycin assay levels are shown in Table 3.  Comparison of the two 
groups indicated that there was no statistical difference between them at the 5% level. 
 
The serum tobramycin levels for both groups are shown in Figure 1.  Although the 
levels were higher at each time interval, there was no statistical difference between the 
groups at any of the time points. 
 
The serum creatinine levels of both groups are shown in Figure 2. These were 
statistically significant at the 5% level at every time interval.  Bonferroni’s correction 
was applied at each time point.   
 
Urinary excretion of tobramycin was maximal in the period 3 to 12 hours after insertion 
of the prosthesis in both groups, and these values were significantly different at the 5% 
level between the two groups (p=0.012 at 3 hours, p=0.009 at 12 hours).  These were 
not significant at the other time points.  Urinary tobramycin excretion is shown in 
Figure 3. 
 
Correlation between the peak tobramycin and peak creatinine levels for each patient was 
performed.  As this data was normally distributed, the Pearson correlation coefficient 
was calculated as –0.416 which was not significant statistically (p=0.411).  
  
Page 6
 
DISCUSSION 
Tobramycin is an aminoglycoside closely related to gentamicin.  At levels seen at the 
operative site, it has a similar spectrum of activity, but is slightly more active against 
Pseudomonas and is less ototoxic and nephrotoxic than gentamicin11,13.  Its elution 
characteristics are superior to gentamicin8.  It is therefore an attractive alternative as an 
additive to acrylic bone cement in the prevention of periprosthetic infection. 
 
Studies have demonstrated very high local concentrations of tobramycin with minimal 
systemic absorption and no systemic side effects when using tobramycin powder mixed 
with cement in the operating suite1,10,14.   Our study demonstrates effective and safe 
local delivery of tobramycin in patients with renal dysfunction by the commercially 
available Simplex-Tobramycin bone cement.  Levels achieved at the operative site were 
similar in both groups and far in excess of the minimum inhibitory concentration for 
common pathogenic bacteria, even after 48 hours6,9,11.   
 
Systemic absorption was minimal in both groups.  Both groups had their average peak 
tobramycin at 3 hours with a gradual decline to negligible levels at 72 hours.  Although 
the renal group had higher systemic concentrations at all time periods, it was not 
significant.  The average peak serum tobramycin levels for each group were below 
2mg/L and the peak in any one patient was 2.1mg/L for one time interval only.  
Although sustained elevations above 2mg/L are not recommended, the threshold for 
nephrotoxicity is said to be 6.0-12.0 mg/L9,11.   
 
Serum creatinine was significantly higher in the renal group throughout the study with 
both groups dropping their average values at 3 hours with a gradual rise back to 
preoperative levels at 72 hours.  This dip probably represents a fluid load from the 
perioperative period resulting in dilution and a drop in serum creatinine.  At 72 hrs, no 
patients in either group had a significant rise from their preoperative levels. 
 
Serum tobramycin was rapidly excreted in both groups in the first 12 hours with a 
gradual decline thereafter.  It was not as rapidly excreted in the renal group because of 
the renal dysfunction and therefore the serum concentration remained higher for longer 
in this group.  Patients in this study had moderate renal dysfunction, which is 
representative of a group of elective surgical candidates and is clinically relevant.  It is 
hard to extrapolate this data to patients with severe renal dysfunction (dialysis); 
however, these patients may not be suitable for elective surgery.  Furthermore, we did 
not find any correlation between peak serum tobramycin levels and creatinine, so it is 
probably safe in that population as well.   
 
Simplex-Tobramycin bone cement delivers very high local bactericidal concentrations 
of tobramycin.  Systemic absorption is minimal, with rapid renal excretion in patients 
with renal dysfunction.  Based on this study, the pharmacokinetic profile of Simplex-
Tobramycin bone cement appears to be appropriate for use in elective total hip 
replacement in patients with renal dysfunction. 
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Figure 1.  Serum tobramycin levels at each time point. 
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Figure 2.  Serum creatinine levels at each time point. 
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Urinary Tobramycin Excretion
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Figure 3.  Urinary excretion of tobramycin at each time point 
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Table 1: Timing of post-operative specimen collection. 
Pharmacokinetic 
Evaluation Pre-op 1 hour
א 3 hours 12 hours 24 hours 48 hours 72 hours 
Blood √ √ √ √ √ √ √ 
Wound Exudate  √ √  √ √  
Urine   √ √ √ √  
א Time 0 is time of femoral insertion of cement. 
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Table 2. Patient demographics 
Case 
Number 
Group Sex Age Height 
(cms) 
Weight 
(kg) 
Plasma 
creatinine 
1 A F 51 173 89 0.07 
2 A M 67 169 92 0.09 
3 A F 89 156 77 0.08 
4 A F 66 167 74 0.09 
5 A M 74 161 75 0.1 
6 A M 73 173 91 0.09 
7 A F 81 155 69 0.08 
8 A F 51 167 59 0.07 
9 A M 79 179 94 0.07 
Mean 
(SD) 
n = 9 M/F 
4/5 
70.1 
(12.9) 
166.7 
(8.1) 
80.0 
(12.1) 
0.08* 
(0.01) 
10 B F 83 158 59 0.16 
11 B M 77 182 97 0.21 
12 B F 49 164 63 0.11 
13 B M 76 166 75 0.18 
14 B F 67 152 70 0.15 
15 B M 62 172 75 0.17 
Mean 
(SD) 
n = 6 M/F 
3/3 
69.0 
(12.3) 
165.7 
(10.5) 
73.2 
(13.3) 
0.16* 
(0.03) 
• significant at 5% level 
• Group A: normal renal function group 
• Group B: renal dysfunction group 
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Table 3.  Mean (SD) for drainage tobramycin levels.  P-values are those obtained when 
tested using Mann-Whitney U-test. 
Time point Normal renal function Renal dysfunction p-value 
1 hour 103.0 (42.9) 90.3 (26.3) 0.727 
3 hours 70.9 (40.3) 71.5 (21.3) 0.689 
24 hours 37.3 (13.9) 39.0 (11.4) 0.864 
48 hours 15.8 (4.9) 20.8 (18.9) 0.683 
* significant at 5% level 
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